Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib in Oral Precancerous Lesions
NCT00052611Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2002
- Primary completion
- Mar 2005
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of celecoxib in oral leukoplakia and Head and neck epithelial dysplasia, sponsored by Dana-Farber Cancer Institute. Primary endpoint: Response Rate Of PGE2 at 2 years. Started Jun 2002; status: completed.
02
Drugs
celecoxib
03
Conditions
oral leukoplakiaHead and neck epithelial dysplasia
Beyond the preview
Go deeper on NCT00052611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00052611.